Temozolomide Capsules

Taking ranitidine does not change temozolomide, MTIC, Cmax and AUC. Taking valproic acid can reduce the elimination rate of temozolomide by 5%. The effect of taking dexamethasone, propoxyperazine, phenytoin, carbamazepine, ondansetron, H2 receptor antagonists or phenobarbital on the elimination rate of oral temozolomide is unclear.

Temozolomide

This product is a hard capsule, the contents of which are white to light pink or light brown powder.

This product is used to treat: newly diagnosed glioblastoma multiforme, initially in combination with radiotherapy and then as adjuvant therapy; recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma after conventional treatment.

The first course of treatment for this drug is 28 days. The initial dose is 150 mg/m2 taken orally once a day based on body surface area. Take it for 5 consecutive days in a 28-day treatment cycle. If the absolute neutrophil count (ANC) measured on the 22nd and 29th days (the first day of the next cycle) is ≥1.5×109/L and the platelet count is ≥100×109/L during the treatment cycle, the dose for the next cycle is 200 mg/m2 taken orally based on body surface area, once a day. Take it for 5 consecutive days in a 28-day treatment cycle. During the treatment period, the patient's whole blood count is tested on the 22nd day (21 days after the first dose) or within 48 hours thereafter, and then once a week until the absolute neutrophil count (ANC) is ≥1.5×109/L and the platelet count is ≥100×109/L, then the next cycle of treatment is carried out. During any treatment cycle, if the measured absolute neutrophil count (ANC) is <1.0×109/L or the platelet count is <50×109/L, the dose of the next cycle will be reduced by 50 mg/m2, but must not be lower than the recommended dose of 100 mg/m2.

The most common adverse reactions are nausea and vomiting. Bone marrow suppression may occur, but it can be recovered. Patients should have their blood routine checked regularly. Other common adverse reactions are fatigue, constipation and headache, dizziness, shortness of breath, hair loss, anemia, fever, decreased immunity, etc.

1. It is contraindicated for those who are allergic to this product and its excipients, and for those who are allergic to dacarbazine; 2. It should be used with caution by minors; 3. It is contraindicated for breastfeeding women, and pregnant or pregnant women.

Precautions for children: Use with caution in minors. Precautions for pregnancy and lactation: Contraindicated for lactating women, pregnant or pregnant women. Precautions for the elderly: Not clear yet.

Taking ranitidine does not change temozolomide, MTIC, Cmax and AUC. Taking valproic acid can reduce the elimination rate of temozolomide by 5%. The effect of taking dexamethasone, propoxyperazine, phenytoin, carbamazepine, ondansetron, H2 receptor antagonists or phenobarbital on the elimination rate of oral temozolomide is unclear.

Keep away from light, sealed and stored in a cool place.

20mg

24 months

Beijing SL Pharmaceutical Co., Ltd.

• Founded in:

  1994-12-24

• Address:

  4th Floor, Building 1, Bitongyuan, No. 69, Fushi Road, Haidian District, Beijing

• Tax NO.:

  91110000102299779W

• Registered Funds:

  1,027.35 million yuan

• Website:

  Log in to view

• Email:

  Log in to view